905 / 1481
Take Home Message
• Increasing rationale but controversial for including pelvic
nodes in prostate XRT
– need to define levels of ‘risk’
• Already clinically indicated in other pelvic cancers
– need to participate in ‘clinical trials’
• Be aware of the volume effect
• New technology to improve XRT therapeutic ratio
– USPIO agents to identify nodes
– dw-MRI and dceMRI
– PET (Choline/PSMA) for biological information
– IMRT to reduce toxicity and enable target boosting
– 4D assessments for PTV (IM & SM) & IGRT